Diplo TRT: The Evidence Base Behind His Protocol

What Diplo Has Said About TRT

Diplo disclosed his TRT use during podcast appearances, framing it as part of his broader attention to health and performance as he moved through his 40s. He has described noticing changes in energy, recovery, and body composition before starting therapy. Those statements are public record; the clinical inference that follows from them is labeled as such throughout this article.

The Public Disclosure

Diplo mentioned testosterone therapy in conversations focused on longevity and optimization, consistent with a growing cohort of high-profile men who have normalized discussing hormone health. His account mirrors what clinicians hear routinely: men in their 40s describing fatigue, reduced drive, and slower recovery, symptoms that can accompany declining androgen levels.

It is worth being precise: a celebrity disclosing TRT is not clinical proof of diagnosed hypogonadism. Responsible journalism requires noting that self-reported therapy could reflect a formal diagnosis, a wellness-oriented prescription from a concierge provider, or both. The biochemical threshold for diagnosed hypogonadism, two morning serum total testosterone readings below 300 ng/dL on separate days, is set by the Endocrine Society's 2018 Clinical Practice Guideline [1].

Why Age Matters Clinically

Testosterone declines at roughly 1 to 2% per year after age 30 [2]. By the mid-40s, a meaningful proportion of men fall below clinical thresholds. The European Male Ageing Study (N=3,369) found late-onset hypogonadism prevalence of approximately 2.1% in men aged 40 to 79, rising sharply with age and comorbidity burden [2]. Diplo was born in 1978, placing him squarely in the age range where biochemical decline is both biologically plausible and clinically addressable.

The Diagnostic Criteria TRT Protocols Rest On

A TRT protocol is only as sound as the diagnosis underpinning it. Initiating therapy without confirmed biochemical deficiency exposes patients to unnecessary risk and is outside guideline-endorsed practice.

Biochemical Confirmation

The Endocrine Society specifies that diagnosis requires two morning (7 to 10 AM) fasting serum total testosterone measurements below 300 ng/dL, obtained on separate days, using a reliable assay [1]. The morning window matters because testosterone peaks early in the day; an afternoon draw can underestimate levels by 20 to 30% in younger men [3].

Free testosterone calculation (or direct measurement by equilibrium dialysis) is recommended when total testosterone sits between 300 and 400 ng/dL and symptoms are present, because sex hormone-binding globulin (SHBG) variation can mask functional deficiency [1].

Symptom Criteria

Biochemistry alone is insufficient. The guideline requires the presence of consistent symptoms: reduced libido, fatigue, depressed mood, decreased muscle mass, increased adiposity, or impaired concentration [1]. The American Urological Association's 2018 guideline similarly requires symptom correlation before prescribing [4].

The Testosterone Formulations Used in TRT Protocols

Several delivery methods are FDA-approved for hypogonadism. Each has a distinct pharmacokinetic profile, and protocol selection depends on patient preference, lifestyle, and adherence likelihood.

Injectable Testosterone

Testosterone cypionate and testosterone enanthate are the most widely prescribed options in the United States. Both are long-acting esters administered intramuscularly or subcutaneously. Testosterone cypionate is typically dosed at 100 to 200 mg every two weeks, though many clinicians now favor 50 to 100 mg weekly to reduce peak-to-trough fluctuation [1].

The FDA label for testosterone cypionate indicates dosing individualized to patient response and serum levels [5]. Weekly subcutaneous injections at lower volumes (0.5 mL or less) have improved tolerability and are increasingly common in outpatient TRT practice.

Transdermal Testosterone

Testosterone gels (AndroGel 1%, AndroGel 1.62%, Testim, Vogelxo) and a transdermal solution (Axiron) provide daily dosing with more stable serum levels than biweekly injections. The FDA-approved labeling for AndroGel 1.62% starts dosing at 40.5 mg (2 pump actuations) applied to shoulders or upper arms each morning [6]. Dose titration occurs at day 14 and day 28 based on pre-dose morning serum testosterone.

Transfer to women and children through skin contact is a documented risk. The FDA added a black box warning to all testosterone gels in 2009 addressing secondary exposure [6].

Testosterone Pellets

Subcutaneous pellets (Testopel) release testosterone over 3 to 6 months. A single insertion procedure delivers 150 to 450 mg depending on patient size and measured deficiency. Pellets avoid daily adherence burdens but require a minor in-office procedure and carry small risks of extrusion or infection [1].

The TRAVERSE Trial: Cardiovascular Safety Evidence

Cardiovascular risk was the central uncertainty hanging over TRT for a decade after a 2010 pilot study raised concerns. The TRAVERSE trial resolved much of that uncertainty with the largest randomized controlled trial of TRT to date.

Trial Design and Population

TRAVERSE enrolled 5,246 hypogonadal men aged 45 to 80 with pre-existing cardiovascular disease or elevated cardiovascular risk. Participants were randomized to testosterone gel 1.62% (titrated to maintain serum testosterone 350 to 750 ng/dL) or placebo. Mean follow-up was 33 months [7].

Primary Outcome

The primary endpoint was major adverse cardiovascular events (MACE): nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Testosterone therapy was non-inferior to placebo for MACE (hazard ratio 0.96, 96.09% CI 0.78 to 1.17), confirming no increased risk in this high-risk population. The full results were published in the New England Journal of Medicine in 2023 [7].

The FDA subsequently updated testosterone labeling in 2024 to reflect the TRAVERSE findings, removing language that had warned broadly of elevated cardiovascular risk in all patients [8].

Secondary Safety Signals

TRAVERSE did identify higher rates of atrial fibrillation (hazard ratio 1.35), pulmonary embolism (hazard ratio 1.92), and acute kidney injury in the testosterone group [7]. These findings inform the monitoring protocols clinicians use, specifically screening for venous thromboembolism risk before initiation and monitoring hematocrit, since erythrocytosis raises blood viscosity and clot risk.

Efficacy Evidence: What TRT Actually Changes

Beyond safety, the question is whether TRT delivers measurable clinical benefit. Several large randomized trials address this directly.

The Testosterone Trials (TTrials)

The TTrials were a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL. Published results across 2016 to 2017 showed [8]:

• Sexual function improved significantly with testosterone vs. Placebo (sexual activity score increase of 0.58 on an 11-point scale, P<0.001) per the NEJM 2016 Sexual Function Trial [9].
• Physical function (6-minute walk distance) did not improve significantly over 12 months in the mobility trial [10].
• Mood and depressive symptoms showed modest but statistically significant improvement in men with baseline depressive symptoms [11].

These trials establish that TRT is not a broad performance enhancer. Benefits are concentrated in sexual function and, to a lesser degree, mood, in men with confirmed biochemical deficiency.

Bone Density

The TTrials bone sub-study (N=211) found that testosterone therapy over 12 months increased volumetric bone density at the spine by 7.5% and at the hip by 4.1% compared to placebo (P<0.001), as reported in JAMA Internal Medicine 2017 [12]. These gains are clinically meaningful for men at fracture risk.

Body Composition

A meta-analysis published in The Journal of Clinical Endocrinology and Metabolism (2016) pooling 52 randomized controlled trials (N=3,016) found testosterone therapy reduced fat mass by a mean of 1.6 kg and increased lean mass by 1.6 kg compared to placebo [13]. Effects were modest at standard therapeutic doses and more pronounced with higher doses outside typical TRT ranges.

Monitoring Protocols: What Responsible TRT Looks Like

Starting TRT without a monitoring plan is a clinical error. The Endocrine Society guideline specifies a structured follow-up schedule [1].

Laboratory Monitoring Timeline

At 3 months after initiation: measure serum total testosterone (target 400 to 700 ng/dL for most formulations), hematocrit, and PSA. At 6 months: repeat all three. Annually thereafter if stable [1].

Hematocrit above 54% warrants dose reduction or temporary discontinuation given the erythrocytosis risk seen in TRAVERSE [7]. PSA rise greater than 1.4 ng/mL above baseline in 12 months, or any single reading above 4.0 ng/mL, warrants urology referral before continuing therapy [1].

Cardiovascular and Metabolic Parameters

Blood pressure, lipid panel, and fasting glucose should be assessed at baseline and at 12 months. Testosterone modestly raises LDL in some patients while reducing HDL; the net cardiovascular effect at physiologic replacement doses is neutral based on TRAVERSE data [7].

The American Heart Association's 2023 scientific statement on androgens and cardiovascular risk recommends individual risk stratification before initiating TRT in men with established coronary artery disease [14].

Fertility Preservation Considerations

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing LH and FSH, which in turn shuts down spermatogenesis. Men who want to preserve fertility should not start standard TRT without discussion of alternatives. Human chorionic gonadotropin (hCG) at 500 to 1,000 IU subcutaneously three times weekly can maintain intratesticular testosterone and spermatogenesis while on TRT [1]. Clomiphene citrate 25 to 50 mg orally every other day is an off-label alternative that stimulates endogenous testosterone production without suppressing sperm production [15].

Lifestyle Factors That Interact With TRT Outcomes

TRT does not operate in isolation. Sleep, exercise, body composition, and alcohol use all influence androgen levels and how patients respond to therapy.

Sleep and Testosterone

A University of Chicago study (N=10) published in JAMA (2011) found that restricting sleep to five hours per night for one week reduced daytime testosterone by 10 to 15% in young healthy men [16]. In a man already borderline deficient, poor sleep may both cause the low reading and blunt the therapeutic response to TRT.

Resistance Training

Resistance exercise acutely raises testosterone and may improve sensitivity to androgen signaling in muscle tissue. A meta-analysis in Sports Medicine (2021) covering 31 studies found resistance training produced small but consistent increases in resting testosterone in men [17]. Clinicians typically recommend structured resistance training as an adjunct to TRT, not a replacement for it in biochemically deficient men.

Body Fat and SHBG

Adipose tissue converts testosterone to estradiol via aromatase. Men with higher body fat percentages tend to have lower free testosterone and higher estradiol, compounding the effect of age-related decline. Losing 5 to 10% of body weight through diet or GLP-1 receptor agonist therapy (such as semaglutide 2.4 mg weekly) has been shown to raise endogenous testosterone in obese hypogonadal men without exogenous replacement, per a 2014 study in the European Journal of Endocrinology [18].

The Endocrine Society's Position on TRT in Older Men

The 2018 Endocrine Society Clinical Practice Guideline states: "We suggest that clinicians consider offering testosterone therapy to men with age-related decline in testosterone levels and consistent symptoms after discussing the potential risks and uncertain benefits" [1]. That language reflects genuine clinical nuance: benefits are real but moderate, and not every symptomatic man needs or benefits from therapy.

The guideline explicitly states: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term" [1]. This absolute contraindication applies regardless of symptom severity.

Men under 18 years of age, those with breast or prostate cancer, uncontrolled heart failure (NYHA class III or IV), hematocrit above 54%, or untreated severe obstructive sleep apnea are listed as contraindications to initiation [1].

What a Typical TRT Protocol Looks Like in Practice

A responsible outpatient TRT protocol for a man in his mid-40s with confirmed hypogonadism generally follows this sequence:

1. Two fasting morning serum total testosterone measurements below 300 ng/dL on separate days, plus LH and FSH to classify primary vs. Secondary hypogonadism.
2. Baseline labs: complete blood count, metabolic panel, lipid panel, PSA, hematocrit.
3. Formulation selection based on lifestyle: weekly subcutaneous testosterone cypionate 80 to 100 mg is the most common starting point for men who self-inject; transdermal gel for those who prefer daily application without injections.
4. Three-month follow-up draw (morning, pre-injection trough for injectables) targeting 400 to 700 ng/dL total testosterone.
5. Dose adjustment if trough is below 350 or above 750 ng/dL.
6. Annual monitoring once stable, with attention to hematocrit, PSA, and cardiovascular parameters.

For a man like Diplo, training heavily and traveling frequently, weekly self-injection with testosterone cypionate is a likely practical choice. That is clinical inference, not confirmed fact, and labeled as such.